BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 18594001)

  • 1. Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer.
    Ohe Y; Ichinose Y; Nakagawa K; Tamura T; Kubota K; Yamamoto N; Adachi S; Nambu Y; Fujimoto T; Nishiwaki Y; Saijo N; Fukuoka M
    Clin Cancer Res; 2008 Jul; 14(13):4206-12. PubMed ID: 18594001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer.
    Seiwert TY; Connell PP; Mauer AM; Hoffman PC; George CM; Szeto L; Salgia R; Posther KE; Nguyen B; Haraf DJ; Vokes EE
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):515-22. PubMed ID: 17255273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer.
    Clarke SJ; Boyer MJ; Millward M; Underhill C; Moylan E; Yip D; White S; Childs A; Beale P; Latz J; Suri A; Iglesias JL
    Lung Cancer; 2005 Sep; 49(3):401-12. PubMed ID: 15923057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial.
    Scagliotti GV; Kortsik C; Dark GG; Price A; Manegold C; Rosell R; O'Brien M; Peterson PM; Castellano D; Selvaggi G; Novello S; Blatter J; Kayitalire L; Crino L; Paz-Ares L
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):690-6. PubMed ID: 15701857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours.
    Nakagawa K; Kudoh S; Matsui K; Negoro S; Yamamoto N; Latz JE; Adachi S; Fukuoka M
    Br J Cancer; 2006 Sep; 95(6):677-82. PubMed ID: 16940981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, double-blind, phase II study of two doses of pemetrexed as first-line chemotherapy for advanced breast cancer.
    Llombart-Cussac A; Martin M; Harbeck N; Anghel RM; Eniu AE; Verrill MW; Neven P; De Grève J; Melemed AS; Clark R; Simms L; Kaiser CJ; Ma D
    Clin Cancer Res; 2007 Jun; 13(12):3652-9. PubMed ID: 17575230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pemetrexed monotherapy versus pemetrexed plus platinum combination as second-line treatment for advanced non-small cell lung cancer.
    Zhang YF; Chen ZW; Lu S
    Chin Med J (Engl); 2009 Oct; 122(20):2472-6. PubMed ID: 20079162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pemetrexed: a multitargeted antifolate.
    Rollins KD; Lindley C
    Clin Ther; 2005 Sep; 27(9):1343-82. PubMed ID: 16291410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenocarcinoma has an excellent outcome with pemetrexed treatment in Korean patients: a prospective, multicenter trial.
    Lee HY; Ahn MJ; Park YH; Ahn JS; Kim BS; Kim HK; Kim HT; Ryoo HM; Bae SH; Lee SS; Choi K; Hong DS; Lee KH; Kwon JH; Choi IS; Kim BS; Lee NS; Gong SJ; Park K
    Lung Cancer; 2009 Dec; 66(3):338-43. PubMed ID: 19299031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and toxicity of pemetrexed as a third-line treatment for non-small cell lung cancer.
    Sun JM; Lee KW; Kim JH; Kim YJ; Yoon HI; Lee JH; Lee CT; Lee JS
    Jpn J Clin Oncol; 2009 Jan; 39(1):27-32. PubMed ID: 18952704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer.
    Scagliotti GV; Germonpré P; Bosquée L; Vansteenkiste J; Gervais R; Planchard D; Reck M; De Marinis F; Lee JS; Park K; Biesma B; Gans S; Ramlau R; Szczesna A; Makhson A; Manikhas G; Morgan B; Zhu Y; Chan KC; von Pawel J
    Lung Cancer; 2010 Jun; 68(3):420-6. PubMed ID: 19692142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pemetrexed combined with paclitaxel in patients with advanced or metastatic non-small-cell lung cancer: a phase I-II trial.
    Stathopoulos GP; Dimitroulis J; Toubis M; Katis C; Karaindros D; Stathopoulos J; Koutandos J
    Lung Cancer; 2007 Jul; 57(1):66-71. PubMed ID: 17382431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I and pharmacokinetic study of pemetrexed plus cisplatin in chemonaive patients with locally advanced or metastatic malignant pleural mesothelioma or non-small cell lung cancer.
    Dickgreber NJ; Fink TH; Latz JE; Hossain AM; Musib LC; Thomas M
    Clin Cancer Res; 2009 Jan; 15(1):382-9. PubMed ID: 19118069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function.
    Mita AC; Sweeney CJ; Baker SD; Goetz A; Hammond LA; Patnaik A; Tolcher AW; Villalona-Calero M; Sandler A; Chaudhuri T; Molpus K; Latz JE; Simms L; Chaudhary AK; Johnson RD; Rowinsky EK; Takimoto CH
    J Clin Oncol; 2006 Feb; 24(4):552-62. PubMed ID: 16391300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma.
    Scagliotti GV; Shin DM; Kindler HL; Vasconcelles MJ; Keppler U; Manegold C; Burris H; Gatzemeier U; Blatter J; Symanowski JT; Rusthoven JJ
    J Clin Oncol; 2003 Apr; 21(8):1556-61. PubMed ID: 12697881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium.
    Sweeney CJ; Roth BJ; Kabbinavar FF; Vaughn DJ; Arning M; Curiel RE; Obasaju CK; Wang Y; Nicol SJ; Kaufman DS
    J Clin Oncol; 2006 Jul; 24(21):3451-7. PubMed ID: 16849761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pemetrexed single agent in previously treated non-small cell lung cancer: a multi-institutional observational study.
    Bearz A; Garassino I; Cavina R; Favaretto A; Boccalon M; Talamini R; Berretta M; Spazzapan S; Simonelli C; Santoro A; Tirelli U
    Lung Cancer; 2008 May; 60(2):240-5. PubMed ID: 18022729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of pemetrexed as maintenance treatment in advanced NSCLC: a Phase III randomized trial.
    Gridelli C; Di Maio M
    Expert Opin Pharmacother; 2010 Feb; 11(2):321-4. PubMed ID: 20053140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of pemetrexed in combination with cisplatin for malignant pleural mesothelioma: a phase I/II study in Japanese patients.
    Nakagawa K; Yamazaki K; Kunitoh H; Hida T; Gemba K; Shinkai T; Ichinose Y; Adachi S; Nambu Y; Saijo N; Fukuoka M
    Jpn J Clin Oncol; 2008 May; 38(5):339-46. PubMed ID: 18434338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of pemetrexed and carboplatin in patients with locally advanced or metastatic breast cancer.
    Garin A; Manikhas A; Biakhov M; Chezhin M; Ivanchenko T; Krejcy K; Karaseva V; Tjulandin S
    Breast Cancer Res Treat; 2008 Jul; 110(2):309-15. PubMed ID: 17851759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.